Picture of Vicarious Surgical logo

RBOT — Vicarious Surgical News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapValue Trap

Vicarious Surgical Inc expected to post a loss of $2.55 a share - Earnings Preview

* Vicarious Surgical Inc  RBOT.N   RBOT.K  is expected
to show no
change in quarterly revenue when it reports  results on November
12 for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Vicarious Surgical Inc
is for
a loss of $2.55 per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vicarious
Surgical Inc is $10.00​, above​ its last closing price of $8.40.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -2.81       -2.77      -2.59     Beat    6.7
 Mar. 31 2024  -2.81       -2.85      -3.00     Missed  -5.3
 Dec. 31 2023  -3.73       -3.75      -1.80     Beat    52​
 Sep. 30 2023  -3.95       -4.27      -3.00     Beat    29.8
 ​​Jun.        -4.44       -4.27      -3.60     Beat    15.8
 30 2023                                                
 Mar. 31 2023  -4.05       -4.05      -6.30     Missed  -55.6​
 Dec. 31 2022  -5.40       -5.20      -2.70     Beat    48.1
 Sep. 30 2022  -4.71       -4.65      -6.00     Missed  -29
 This summary was machine generated November 9 at 00:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Vicarious Surgical

See all news